Weakening effect of famotidine but not of nizatidine on the mucus-bicarbonate barrier of the human stomach.
Twenty outpatients with various duodenal disorders but endoscopically normal gastric mucosa were randomly treated for 4 weeks with either nizatidine (300 mg h.s.) or famotidine (40 mg h.s.). Before and after treatment quantitative and qualitative evaluations of gastric mucus secretion as well as measurement of gastric bicarbonate output were performed. No changes in the mucus-bicarbonate barrier were observed after nizatidine treatment. In contrast, famotidine was found to impair the quality of mucus, thus weakening the mucosal defences against re-ulceration after treatment withdrawal.
Guslandi
M
M
Institute of Internal Medicine, University of Milan, Italy.
Battaglia
A
A
Pamparana
F
F
Passaretti
S
S
Pellegrini
A
A
Tittobello
A
A
D000328:Adult; D000368:Aged; D001639:Bicarbonates / Q000378:metabolism*; D015738:Famotidine / Q000494:pharmacology*; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects* / Q000378:metabolism; D006635:Histamine H2 Antagonists / Q000494:pharmacology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009093:Mucus / Q000378:metabolism; D016567:Nizatidine; D013844:Thiazoles / Q000494:pharmacology*
D001639:Bicarbonates; D006635:Histamine H2 Antagonists; D013844:Thiazoles; D015738:Famotidine; D016567:Nizatidine